Pharma Equity Group A

Pharma Equity Group A/S is a Danish biopharmaceutical company focused on the development of novel treatments for patients with unmet medical needs through its subsidiary, Reponex Pharmaceuticals. The company utilizes a drug repurposing strategy, taking known and approved active substances and applying them to new indications via innovative delivery methods. Its clinical pipeline primarily targets chronic wounds, inflammatory bowel diseases such as ulcerative colitis and pouchitis, and certain types of cancer. Currently, the company has several programs in Phase 2 clinical development, aiming to provide more effective and safer therapeutic options by leveraging established safety profiles of existing drugs. The company is listed on the Nasdaq Copenhagen exchange under the symbol PEG.